Table 1 Study population characteristics (n = 36)
Median [range] age (yr) | 55 [37-87] |
|---|---|
Histotype # | Â |
   Invasive ductal carcinoma | 28 (77.7%) |
   Invasive lobular carcinoma | 5 (13.8%) |
   Mixed (ductal and lobular) | 2 (5.5%) |
   Undifferentiated | 1 (3.0%) |
Grading° |  |
   G2 | 21 (58.3%) |
   G3 | 15 (41.7%) |
ER status | Â |
   Negative | 14 (38.8%) |
   Positive | 22 (61.2%) |
PgR status | Â |
   Negative | 13 (36.1%) |
   Positive | 23 (63.9%) |
HER2 status* | Â |
   Negative | 27 (75.0%) |
   Positive | 9 (25.0%) |
Adjuvant chemotherapy^ | Â |
   FEC | 18 (52.9%) |
   EC | 11 (32.4%) |
   CMF | 5 (14.7%) |
Mean ± SD time to first relapse (months) | 15.8 ± 6.5 |
Metastatis sites | Â |
   Bone | 21 (58.3%) |
   Liver | 21 (58.3%) |
   Lung | 16 (44.4%) |
   Lymphnodes | 14 (38.8%) |
   Local | 3 (8.3%) |
Chemotherapy" | Â |
   TXT75 | 14 (38.8%) |
   TXT25 | 8 (22.2%) |
   TXT75+C | 5 (13.8%) |
   TXT75+T | 9 (25.2%) |
Treatment best response | Â |
   Complete response | 1 (2.7%) |
   Partial response | 14 (38.8%) |
   Stable disease | 12 (33.3%) |
   Disease progression | 9 (25.2%) |
Time to disease progression (months) | Â |
   Median [range] | 9 [2-54] |
Overall survival (months) | Â |
   Median [range] | 20 [3-101] |